Artificial Intelligence based Modern Approaches to Diagnose Alzheimer’s
Article Sidebar
Main Article Content
Abstract
In current times the level at which Alzheimer’s disease is rising is at an alarming rate. This rise points to the need for much more accurate and faster modes of diagnosis that the country wants. Artificial intelligence can resolve this issue as it uses extensive human surveys and real-time machine medicine monitors. The use of biomarkers that work on detecting unusual changes in the brain and the spectrochemical analysis of blood that works on the principle of vibrational spectroscopy Inclusive of Raman spectroscopy and FTIR cannot be used at a large scale. The underemployment of these methods includes the requirement of highly trained professionals and the heterogeneous nature of the human population. Therefore, the following approaches may be employed to overcome these benefits and give individuals optimal health solutions; Random Forest technique, etc., artificial neural network. When the talk is shifted towards treating Alzheimer’s, there is no such drug to treat it thoroughly. Symptomatic treatment options are available based on specific known receptors of Alzheimer’s etiology. Artificial intelligence has also taken a pioneering step to fill this void. With its help, we can identify a lot more receptors influenced upon Alzheimer’s advent. Once these newly found receptors are considered, better symptomatic treatment can be provided. Drug classes like NMDA receptor antagonists, Statins, and Antipsychotics are readily available options for managing disease, but all of these have a low safety index and other side effects like bleeding and psychosis. Newly re-purposed drugs like Acitretin and minocycline etc., have minimalistic side effects and high safety margin, making them a better choice in the diseased state. After Artificial intelligence has entered the market, the fields of diagnostics and therapeutics and taken the most advantage of it alongside administration and regulation, therefore, this AI is a boon in the medical industry as it can help manage medicine-based disease registries and population management when it comes to Alzheimer’s diagnosis and treatment.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
References
Holzinger A, Langs G, Denk H, Zatloukal K, Müller H. Causability and explainability of artificial intelligence in medicine. Wiley Interdiscip Rev Data Min Knowl Discov. 2019;9(4):1–13. [CrossRef]
Schmidhuber J. Deep Learning in neural networks: An overview. Neural Networks [Internet]. 2015; 61:85–117. Available from: http://dx.doi.org/10.1016/j.neunet.2014.09.003[CrossRef]
Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature [Internet]. 2017;542(7639):115–8. Available from: http://dx.doi.org/10.1038/nature21056[CrossRef]
Ting DSW, Cheung CYL, Lim G, Tan GSW, Quang ND, Gan A, et al. Development and validation of a deep learning system for diabetic retinopathy and related eye diseases using retinal images from multiethnic populations with diabetes. JAMA - J Am Med Assoc. 2017;318(22):2211–23. [CrossRef]
Monteleone M. NooJ local grammars and formal semantics: Past participles vs. adjectives in Italian. Commun Comput Inf Sci.
;607(8):83–95. [CrossRef]
Holzinger A. Trends in Interactive Knowledge Discovery for Personalized Medicine: Cognitive Science meets Machine Learning. IEEE Intell Informatics Bull [Internet]. 2014;15(1):6–14. Available from: http://www.comp.hkbu.edu.hk/~cib/2014/Dec/article2/iib_vol15no1_article2.pdf
Holzinger A. Introduction to MAchine Learning & Knowledge Extraction (MAKE). Mach Learn Knowl Extr. 2017;1(1):1–20. [CrossRef]
Tang A, Tam R, Cadrin-Chênevert A, Guest W, Chong J, Barfett J, et al. Canadian Association of Radiologists White Paper on Artificial Intelligence in Radiology. Can Assoc Radiol J. 2018;69(2):120–35. [CrossRef]
Kermany DS, Goldbaum M, Cai W, Valentim CCS, Liang H, Baxter SL, et al. Identifying Medical Diagnoses and Treatable Diseases by Image-Based Deep Learning. Cell [Internet]. 2018;172(5):1122-1131.e9. Available from: https://doi.org/10.1016/j.cell.2018.02.010[CrossRef]
He J, Baxter SL, Xu J, Xu J, Zhou X, Zhang K. The practical implementation of artificial intelligence technologies in medicine. Nat Med [Internet]. 2019;25(1):30–6. Available from: http://dx.doi.org/10.1038/s41591-018-0307-0[CrossRef]
Chernew ME, Landrum MB. Targeted Supplemental Data Collection — Addressing the Quality-Measurement Conundrum. N Engl J Med. 2018;378(11):979–81. [CrossRef]
Association A. 2018 Alzheimer’s disease facts and figures. Alzheimer’s Dement [Internet]. 2018;14(3):367–429. Available from: https://doi.org/10.1016/j.jalz.2018.02.001[CrossRef]
Isacson O, Seo H, Lin L, Albeck D, Granholm AC. Alzheimer’s disease and Down’s syndrome: Roles of APP, trophic factors and ACh. Trends Neurosci. 2002;25(2):79–84. [CrossRef]
Edwards FA. A Unifying Hypothesis for Alzheimer’s Disease: From Plaques to Neurodegeneration. Trends Neurosci [Internet]. 2019;42(5):310–22. Available from: https://doi.org/10.1016/j.tins.2019.03.003[CrossRef]
Morris GP, Clark IA, Vissel B. Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer’s disease. Acta Neuropathol [Internet]. 2018;136(5):663–89. Available from: https://doi.org/10.1007/s00401-018-1918-8[CrossRef]
Mittelman MS, Ferris SH, Steinberg G, Shulman E, Mackell JA, Ambinder A, et al. An intervention that delays institutionalization of alzheimer’s disease patients: Treatment of spouse-caregivers. Gerontologist. 1993;33(6):730–40. [CrossRef]
Finkel SI, e Silva JC, Cohen GD, Miller S, Sartorius N. Behavioral and psychological symptoms of dementia: A consensus statement on current knowledge and implications for research and treatment. Am J Geriatr Psychiatry. 1998;6(2):97–100. [CrossRef]
Van Der Mussele S, Fransen E, Struyfs H, Luyckx J, Mariën P, Saerens J, et al. Depression in mild cognitive impairment is associated with progression to alzheimer’s disease: A longitudinal study. J Alzheimer’s Dis. 2014;42(4):1239–50. [CrossRef]
Chan DC, Kasper JD, Black BS, Rabins P V. Presence of behavioral and psychological symptoms predicts nursing home placement in community-dwelling elders with cognitive impairment in univariate but not multivariate analysis. Journals Gerontol - Ser A Biol Sci Med Sci. 2003;58(6):548–54. [CrossRef]
Baumgarten M, Battista RN, Infante-Rivard C, Hanley JA, Becker R, Gauthier S. The psychological and physical health of family members caring for an elderly person with dementia. J Clin Epidemiol. 1992;45(1):61–70. [CrossRef]
Cohen CA, Shulman KI, Wortley JT, Gold DP, McDonald G, Wargon M. Factors determining the decision to institutionalize dementing individuals:A prospective study. Gerontologist. 1993;33(6):714–20. [CrossRef]
De Vugt ME, Nicolson NA, Aalten P, Lousberg R, Jolle J, Verhey FRJ. Behavioral problems in dementia patients and salivary cortisol patterns in caregivers. J Neuropsychiatry Clin Neurosci. 2005;17(2):201–7. [CrossRef]
Kiecolt-Glaser JK, Dura JR, Speicher CE, Trask OJ, Glaser R. Spousal caregivers of dementia victims: Longitudinal changes in immunity and health. Psychosom Med. 1991;53(4):345–62. [CrossRef]
Buccafusco JJ. The cholinergic hypothesis — past and present. Cogn Enhancing Drugs. 2004;1–10. [CrossRef]
Parihar MS, Hemnani T. Alzheimer’s disease pathogenesis and therapeutic interventions. J Clin Neurosci. 2004;11(5):456–67. [CrossRef]
Chen KS, Tuszynski MH, Gage FH. Role of neurotrophic factors in Alzheimer’s disease. Neurobiol Aging. 1989;10(5):545–6. [CrossRef]
Checler F, Vincent B. Alzheimer’s and prion diseases: Distinct
pathologies, common proteolytic denominators. Trends Neurosci. 2002;25(12):616–20. [CrossRef]
Grigorenko AP, Rogaev EI. Molecular basics of Alzheimer’s disease. Mol Biol (Mosk). 2007;41(2):331–45. [CrossRef]
Kar N. Behavioral and psychological symptoms of dementia and their management. Indian J Psychiatry [Internet]. 2009 Jan;51 Suppl 1(Suppl1):S77–86. Available from: https://pubmed.ncbi.nlm.nih.gov/21416023[CrossRef]
Chan DC, Kasper JD, Black BS, Rabins P V. Prevalence and correlates of behavioral and psychiatric symptoms in community-dwelling elders with dementia or mild cognitive impairment: The Memory and Medical Care Study. Int J Geriatr Psychiatry. 2003;18(2):174–82. [CrossRef]
Nestor PJ, Scheltens P, Hodges JR. Advances in the early detection of Alzheimer’ s disease. 2004;(July):34–41. [CrossRef]
Dauwels J, Srinivasan K, Reddy MR, Musha T, Latchoumane C, Jeong J, et al. Slowing and Loss of Complexity in Alzheimer’ s EEG : Two Sides of the Same Coin ? 2011;2011. [CrossRef]
Dauwels J, Vialatte F, Cichocki A. Diagnosis of Alzheimer’s Disease from EEG Signals: Where Are We Standing? Curr Alzheimer Res. 2010;999(999):1–19. [CrossRef]
Jelles B, Van Birgelen JH, Slaets JPJ, Hekster REM, Jonkman EJ, Stam CJ. Decrease of non-linear structure in the EEG of Alzheimer patients compared to healthy controls. Clin Neurophysiol. 1999;110(7):1159–67. [CrossRef]
Houmani N, Dreyfus G, Vialatte FB. Epoch-based Entropy for Early Screening of Alzheimer’ s Disease. 2015;25(8):1–18. [CrossRef]
Sankari Z, Adeli H, Adeli A. Wavelet Coherence Model for Diagnosis of Alzheimer Disease. 2012;00(0):1–11.
Movasaghi Z, Rehman S, Rehman I. Fourier Transform Infrared (FTIR) Spectroscopy of Biological Tissues. 2018;4928(January).
Jones SAV, Brien JTO. The prevalence and incidence of dementia with Lewy bodies: a systematic The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. 2013;(March).
Rossini PM, Di Iorio R, Vecchio F, Anfossi M, Babiloni C, Bozzali M, et al. Early diagnosis of Alzheimer’s disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts. Clin Neurophysiol [Internet]. 2020;131(6):1287–310. Available from: https://doi.org/10.1016/j.clinph.2020.03.003 [CrossRef]
Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-gateau P, et al. Revising the defi nition of Alzheimer’ s disease: a new lexicon. 2010;9(November). [CrossRef]
Bruni AC. Cloning of a gene bearing missense mutations in early onset familial Alzheimer’s disease: A Calabrian study. Vol. 13, Functional Neurology. 1998. p. 257–61.
Tang M, Ryman DC, McDade E, Jasielec MS, Buckles VD, Cairns NJ, et al. Neurological manifestations of autosomal dominant familial Alzheimer’s disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurol [Internet]. 2016;15(13):1317–25. Available from: http://dx.doi.org/10.1016/S1474-4422(16)30229-0 [CrossRef]
Petersen RC, Lopez O, Armstrong MJ, Getchius TSD, Ganguli M, Gloss D, et al. Practice guideline update summary: Mild cognitive impairment report of theguideline development, dissemination, and implementation. Neurology. 2018;90(3):126–35. [CrossRef]
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183–94. [CrossRef]
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria. Vol. 12, Alzheimer’s and Dementia. 2016. 292–323 p. [CrossRef]
Wilmer HH, Sherman LE, Chein JM. Smartphones and cognition: A review of research exploring the links between mobile technology habits and cognitive functioning. Front Psychol. 2017;8(APR):1–16. [CrossRef]
Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9(1):119–28. [CrossRef]
Caroli A, Frisoni GB. The dynamics of Alzheimer’s disease biomarkers in the Alzheimer’s Disease Neuroimaging Initiative cohort. Neurobiol Aging [Internet]. 2010;31(8):1263–74. Available
from:http://dx.doi.org/10.1016/j.neurobiolaging.2010.04.024[CrossRef]
Schuff N, Tosun D, Insel PS, Chiang GC, Truran D, Aisen PS, et al. Nonlinear time course of brain volume loss in cognitively normal and impaired elders. Neurobiol Aging [Internet]. 2012;33(5):845–55. Available from: http://dx.doi.org/10.1016/j.neurobiolaging.2010.07.012 [CrossRef]
Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet. 2006;368(9533):387–403. [CrossRef]
Olsson B, Lautner R, Andreasson U, Öhrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673–84. [CrossRef]
Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403–13. [CrossRef]
Parvizi J, Kastner S. Promises and limitations of human intracranial electroencephalography. Nat Neurosci [Internet]. 2018;21(4):474–83. Available from: http://dx.doi.org/10.1038/s41593-018-0108-2 [CrossRef]
Mattsson N, Roseń E, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology. 2012;78(7):468–76. [CrossRef]
Cedazo-Minguez A, Winblad B. Biomarkers for Alzheimer’s disease and other forms of dementia: Clinical needs, limitations and future aspects. Exp Gerontol [Internet]. 2010;45(1):5–14. Available from: http://dx.doi.org/10.1016/j.exger.2009.09.008[CrossRef]
Dos Santos TC, Gomes TM, Pinto BAS, Camara AL, De Andrade Paes AM. Naturally occurring acetylcholinesterase inhibitors and their potential use for Alzheimer’s disease therapy. Front Pharmacol. 2018;9(OCT):1–14. [CrossRef]
Inhibitors A, Receptor N, Glynn-servedio BE, Ranola TS, Ad M, Ad M, et al. With Food. Consult Pharm. 2017;32(9):511–8. [CrossRef]
Khoury R, Grysman N, Gold J, Patel K, Grossberg GT. The role of 5 HT6-receptor antagonists in Alzheimer’s disease: an update. Expert Opin Investig Drugs [Internet]. 2018;27(6):523–33. Available from: https://doi.org/10.1080/13543784.2018.1483334[CrossRef]
Sierra S, Ramos MC, Molina P, Esteo C, Vázquez JA, Burgos JS. Statins as neuroprotectants: A comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimer’s Dis. 2011;23(2):307–18. [CrossRef]
Eckert GP, Wood WG, Müller WE. Statins: Drugs for Alzheimer’s disease? J Neural Transm. 2005;112(8):1057–71. [CrossRef]
Ballard C, Howard R. Neuroleptic drugs in dementia: Benefits and harm. Nat Rev Neurosci. 2006;7(6):492–500. [CrossRef]
Zhong K, Tariot P, Mintzer J, Minkwitz M, Devine N. Quetiapine to Treat Agitation in Dementia: A Randomized, Double-Blind,Placebo-Controlled Study. Curr Alzheimer Res. 2007;4(1):81–93. [CrossRef]
Lahmiri S, Shmuel A. Performance of machine learning methods applied to structural MRI and ADAS cognitive scores in diagnosing Alzheimer’s disease. Biomed Signal Process Control [Internet]. 2019; 52:414–9. Available from: https://doi.org/10.1016/j.bspc.2018.08.009 [CrossRef]
Cao P, Liu X, Yang J, Zhao D, Huang M, Zaiane O. ℓ2,1−ℓ1 regularized nonlinear multi-task representation learning based cognitive performance prediction of Alzheimer’s disease. Pattern Recognit [Internet]. 2018; 79:195–215. Available from: https://doi.org/10.1016/j.patcog.2018.01.028 [CrossRef]
de Bruijne M. Machine learning approaches in medical image analysis: From detection to diagnosis. Med Image Anal [Internet]. 2016; 33:94–7. Available from: http://dx.doi.org/10.1016/j.media.2016.06.032[CrossRef]
López M, Ramírez J, Górriz JM, Álvarez I, Salas-Gonzalez D, Segovia F, et al. Principal component analysis-based techniques and supervised classification schemes for the early detection of Alzheimer’s disease. Neurocomputing. 2011;74(8):1260–71. [CrossRef]
El-Dahshan ESA, Hosny T, Salem ABM. Hybrid intelligent techniques for MRI brain images classification. Digit Signal Process A Rev J [Internet]. 2010;20(2):433–41. Available from: http://dx.doi.org/10.1016/j.dsp.2009.07.002 [CrossRef]
Han J, Kamber M, Pei J. Third Edition : Data Mining Concepts and Techniques. J Chem Inf Model [Internet]. 2012;53(9):1689–99. Available from: http://library.books24x7.com/toc.aspx?bkid=44712
Wu X, Kumar V, Ross QJ, Ghosh J, Yang Q, Motoda H, et al. Top 10 algorithms in data mining. Vol. 14, Knowledge and Information Systems. 2008. 1–37 p. [CrossRef]
Illán IA, Górriz JM, López MM, Ramírez J, Salas-Gonzalez D,
Segovia F, et al. Computer aided diagnosis of Alzheimer’s disease using component based SVM. Appl Soft Comput J. 2011;11(2):2376–82. [CrossRef]
Abdulkadir A, Mortamet B, Vemuri P, Jack CR, Krueger G, Klöppel S. Effects of hardware heterogeneity on the performance of SVM Alzheimer’s disease classifier. Neuroimage [Internet]. 2011;58(3):785–92. Available from: http://dx.doi.org/10.1016/j.neuroimage.2011.06.029 [CrossRef]
Amoroso N, Diacono D, Fanizzi A, La Rocca M, Monaco A, Lombardi A, et al. Deep learning reveals Alzheimer’s disease onset in MCI subjects: Results from an international challenge. J Neurosci Methods. 2018;302:3–9. [CrossRef]
Bengio Y. Learning deep architectures for AI. Vol. 2, Foundations and Trends in Machine Learning. 2009. 1–27 p. [CrossRef]
Vieira S, Pinaya WHL, Mechelli A. Using deep learning to investigate the neuroimaging correlates of psychiatric and neurological disorders: Methods and applications. Neurosci Biobehav Rev [Internet]. 2017;74:58–75. Available from: http://dx.doi.org/10.1016/j.neubiorev.2017.01.002 [CrossRef]
Choi KS, Shin JS, Lee JJ, Kim YS, Kim SB, Kim CW. In vitro trans-differentiation of rat mesenchymal cells into insulin-producing cells by rat pancreatic extract. Biochem Biophys Res Commun. 2005;330(4):1299–305. [CrossRef]
Deepika Nair M, Sinta MS, Vidya M. A study on various deep learning algorithms to diagnose alzheimer’s disease [Internet]. Vol. 30, Lecture Notes in Computational Vision and Biomechanics. Springer International Publishing; 2019. 1705–1710 p. Available from: http://dx.doi.org/10.1007/978-3-030-00665-5_157[CrossRef]
Urwyler P, Stucki R, Rampa L, Müri R, Mosimann UP, Nef T. Cognitive impairment categorized in community-dwelling older adults with and without dementia using in-home sensors that recognise activities of daily living. Sci Rep [Internet]. 2017;7(February):1–9. Available from: http://dx.doi.org/10.1038/srep42084[CrossRef]
Leys C, Ley C, Klein O, Bernard P, Licata L. Detecting outliers: Do not use standard deviation around the mean, use absolute deviation around the median. J Exp Soc Psychol [Internet]. 2013;49(4):764–6. Available from: http://dx.doi.org/10.1016/j.jesp.2013.03.013[CrossRef]
Morris S, Patel N, Baio G, Kelly L, Lewis-Holmes E, Omar RZ, et al. Monetary costs of agitation in older adults with Alzheimer’s disease in the UK: Prospective cohort study. BMJ Open. 2015;5(3):1–8. [CrossRef]
Qin SM, Verkasalo H, Mohtaschemi M, Hartonen T, Alava M. Patterns, Entropy, and Predictability of Human Mobility and Life. PLoS One. 2012;7(12). [CrossRef]
Elfaki AO, Alotaibi M. The role of M-health applications in the fight against Alzheimer’s: current and future directions. mHealth. 2018;4:32–32. [CrossRef]
Yeasmin S. Benefits of Artificial Intelligence in Medicine. 2nd Int Conf Comput Appl Inf Secur ICCAIS 2019. 2019;1–6. [CrossRef]
Bravo J, López-De-Ipiña D, Fuentes C, Hervás R, Peña R, Vergara M, et al. Enabling NFC technology for supporting chronic diseases: A proposal for alzheimer caregivers. Lect Notes Comput Sci (including Subser Lect Notes Artif Intell Lect Notes Bioinformatics). 2008;5355 LNCS:109–25. [CrossRef]
Sheri B, Kumari P, Siddiqui IF, Noman H. Artificial Intelligence Based Memory Stash Alzheimer’s Aid. ICISCT 2020 - 2nd Int Conf Inf Sci Commun Technol. 2020; [CrossRef]
Gresham GK, Ehrhardt S, Meinert JL, Appel LJ, Meinert CL. Characteristics and trends of clinical trials funded by the National Institutes of Health between 2005 and 2015. Clin Trials. 2018;15(1):65–74. [CrossRef]
Yeu Y, Yoon Y, Park S. Protein localization vector propagation: a method for improving the accuracy of drug repositioning. Mol Biosyst. 2015;11(7):2096–102. [CrossRef]
Ashburn TT, Thor KB. Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673–83. [CrossRef]
Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, et al. Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest. 2007;117(11):3393–402. [CrossRef]
Torika N, Asraf K, Cohen H, Fleisher-Berkovich S. Intranasal telmisartan ameliorates brain pathology in five familial Alzheimer’s disease mice. Brain Behav Immun [Internet]. 2017; 64:80–90. Available from: http://dx.doi.org/10.1016/j.bbi.2017.04.001[CrossRef]
Ongali B, Nicolakakis N, Tong XK, Aboulkassim T, Papadopoulos P, Rosa-Neto P, et al. Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer’s disease model. Neurobiol Dis [Internet]. 2014; 68:126–36. Available from: http://dx.doi.org/10.1016/j.nbd.2014.04.018[CrossRef]
Wang J, Ono K, Dickstein DL, Arrieta-Cruz I, Zhao W, Qian X, et al. Carvedilol as a potential novel agent for the treatment of Alzheimer’s disease. Neurobiol Aging. 2011;32(12): 2321.e1-2321.e12. [CrossRef]
Sanz JM, Chiozzi P, Colaianna M, Zotti M, Ferrari D, Trabace L, et al. Nimodipine inhibits IL-1ß release stimulated by amyloid ß from microglia. Br J Pharmacol. 2012;167(8):1702–11. [CrossRef]
Ou Z, Kong X, Sun X, He X, Zhang L, Gong Z, et al. Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice. Brain Behav Immun [Internet]. 2018; 69:351–63. Available from: https://doi.org/10.1016/j.bbi.2017.12.009
[CrossRef]
Toba J, Nikkuni M, Ishizeki M, Yoshii A, Watamura N, Inoue T, et al. PPARγ agonist pioglitazone improves cerebellar dysfunction at pre-Aβ deposition stage in APPswe/PS1dE9 Alzheimer’s disease model mice. Biochem Biophys Res Commun [Internet]. 2016;473(4):1039–44. Available from: http://dx.doi.org/10.1016/j.bbrc.2016.04.012 [CrossRef]
Kurata T, Miyazaki K, Kozuki M, Panin VL, Morimoto N, Ohta Y, et al. Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. Brain Res [Internet]. 2011; 1371:161–70. Available from: http://dx.doi.org/10.1016/j.brainres.2010.11.067 [CrossRef]
Niu M, Feng X, Zhou L. The role of the ERK1/2 pathway in simvastatin-loaded nanomicelles and simvastatin in regulating the osteogenic effect in MG63 cells. Int J Nanomedicine. 2018; 13:8165–78. [CrossRef]
Cuadrado-Tejedor M, Hervias I, Ricobaraza A, Puerta E, Pérez-Roldán JM, García-Barroso C, et al. Sildenafil restores cognitive function without affecting β-amyloid burden in a mouse model of Alzheimer’s disease. Br J Pharmacol. 2011;164(8):2029–41. [CrossRef]
Nelson RL, Guo Z, Halagappa VM, Pearson M, Gray AJ, Matsuoka Y, et al. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol. 2007;205(1):166–76. [CrossRef]
Choi Y, Jeong HJ, Liu QF, Oh ST, Koo BS, Kim Y, et al. Clozapine Improves Memory Impairment and Reduces Aβ Level in the Tg-APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease. Mol Neurobiol. 2017;54(1):450–60. [CrossRef]
Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. Proc Natl Acad Sci U S A. 2012;109(42). [CrossRef]
Lin CH, Chen PK, Chang YC, Chuo LJ, Chen YS, Tsai GE, et al. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: A randomized, double-blind, placebo-controlled trial. Biol Psychiatry [Internet]. 2014;75(9):678–85. Available from: http://dx.doi.org/10.1016/j.biopsych.2013.08.010 [CrossRef]
Pierrot N, Lhommel R, Quenon L, Hanseeuw B, Dricot L, Sindic C, et al. Targretin improves cognitive and biological markers in a patient with Alzheimer’s disease. J Alzheimer’s Dis. 2015;49(2):271–6. [CrossRef]
Medina DX, Caccamo A, Oddo S. Methylene blue reduces Aβ levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol. 2011;21(2):140–9. [CrossRef]
Folch J, Petrov D, Ettcheto M, Pedrós I, Abad S, Beas-Zarate C, et al. Masitinib for the treatment of mild to moderate Alzheimer’s disease. Expert Rev Neurother. 2015;15(6):587–96. [CrossRef]
Endres K, Fahrenholz F, Lotz J, Hiemke C, Teipel S, Lieb K, et al. Increased CSF APPs-a levels in patients with Alzheimer disease treated with Acitretin. Neurology. 2014;83(21):1930–5. [CrossRef]
Cai Z, Yan Y, Wang Y. Minocycline alleviates beta-amyloid protein and tau pathology via restraining neuroinflammation induced by diabetic metabolic disorder. Clin Interv Aging. 2013; 8:1089–95. [CrossRef]